Further processing options
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Saved in:
Journal Title: | Annals of Oncology |
---|---|
Authors and Corporations: | , |
In: | Annals of Oncology, 30, 2019, p. iv105 |
Type of Resource: | E-Article |
Language: | English |
published: |
Elsevier BV
|
Subjects: |